The 13C4 monoclonal antibody that neutralizes Shiga toxin type 1 (Stx1) recognizes three regions on the Stx1 B subunit and prevents Stx1 from binding to its eukaryotic receptor globotriaosylceramide

Infection and Immunity

Volumn 74, Issue 12, 2006, Pages 6992-6998

  Smith, Michael J ^a   Carvalho, Humberto M ^a   Melton Celsa, Angela R ^a   O'Brien, Alison D ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLOBOTRIAOSYLCERAMIDE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 13C4; NEUTRALIZING ANTIBODY; PROTEIN SUBUNIT; VEROTOXIN 1;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIGEN BINDING; ARTICLE; BINDING SITE; CONTROLLED STUDY; CRYSTAL STRUCTURE; GENE MUTATION; IMMUNE RESPONSE; IMMUNIZATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; SHIGA TOXIN PRODUCING ESCHERICHIA COLI;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMALS; ANTIBODIES, MONOCLONAL; CRYSTALLOGRAPHY, X-RAY; EPITOPE MAPPING; EPITOPES; MICE; MICE, INBRED STRAINS; MOLECULAR SEQUENCE DATA; PROTEIN CONFORMATION; PROTEIN SUBUNITS; RECEPTORS, CELL SURFACE; RECOMBINANT FUSION PROTEINS; SEQUENCE ALIGNMENT; SHIGA-LIKE TOXIN I; SHIGA-LIKE TOXIN II; TRIHEXOSYLCERAMIDES;

EID: 33845500290     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.01247-06     Document Type: Article

References (35)

1. Ashkenazi, S., and T. G. Cleary. 1989. Rapid method to detect Shiga toxin and Shiga-like toxin I based on binding to globotriosyl ceramide (Gb3), their natural receptor. J. Clin. Microbiol. 27:1145-1150.
2. Boyd, B., S. Richardson, and J. Gariepy. 1991. Serological responses to the B subunit of Shiga-like toxin 1 and its peptide fragments indicate that the B subunit is a vaccine candidate to counter action of the toxin. Infect. Immun. 59:750-757.
3. Bürk, C., R. Dietrich, G. Açar, M. Moravek, M. Bülte, and E. Märtlbauer. 2003. Identification and characterization of a new variant of Shiga toxin I in Escherichia coli ONT:H19 of bovine origin. J. Clin. Microbiol. 41:2106-2112.
4. Centers for Disease Control and Prevention. 2005. Outbreaks of Escherichia coli O157:H7 associated with petting zoos-North Carolina, Florida, and Arizona, 2004 and 2005. Morb. Mortal. Wkly. Rep. 54:1277-1280.
5. Centers for Disease Control and Prevention. 1994. Addressing emerging infectious disease threats: a prevention strategy for the United States (executive summary). Morb. Mortal. Wkly. Rep. 43(RR-5):1-18.
6. Dowling, T. C., P. A. Chavaillaz, D. G. Young, A. Melton-Celsa, A. O'Brien, C. Thuning-Roberson, R. Edelman, and C. O. Tacket. 2005. Phase 1 safety and pharmacokinetic study of chimeric murine-human monoclonal antibody cαStx2 administered intravenously to healthy adult volunteers. Antimicrob. Agents Chemother 49:1808-1812.
7. Edwards, A. C., A. R. Melton-Celsa, K. Arbuthnott, J. R. Stinson, C. K. Schmitt, H. C. Wong, and A. D. O'Brien. 1998. Vero cell neutralization and mouse protective efficacy of humanized monoclonal antibodies against Escherichia coli toxins Stx1 and Stx2, p. 388-392. In J. B. Kaper and A. D. O'Brien (ed.), Escherichia coli O157:H7 and other Shiga toxin-producing E. coli strains. ASM Press, Washington, D.C.
8. Fraser, M. E., M. M. Chernaia, Y. V. Kozlov, and M. N. James. 1994. Crystal structure of the holotoxin from Shigella dysenteriae at 2.5 Å resolution. Nat. Struct. Biol. 1:59-64.
9. Fraser, M. E., M. Fujinaga, M. M. Cherney, A. R. Melton-Celsa, E. M. Twiddy, A. D. O'Brien, and M. N. James. 2004. Structure of Shiga toxin type 2 (Stx2) from Escherichia coli O157:H7. J. Biol. Chem. 279:27511-27517.
10. Henikoff, S., and J. G. Henikoff. 1992. Amino acid substitution matrices from protein blocks. Proc. Natl. Acad. Sci. USA 89:10915-10919.
11. Higuchi, R. 1989. Using PCR to engineer DNA, p. 61-70. In H. A. Erlich (ed.), PCR technology. Stockton Press, New York, N.Y.
12. Kimura, T., M. S. Co, M. Vasquez, S. Wei, H. Xu, S. Tani, Y. Sakai, T. Kawamura, Y. Matsumoto, H. Nakao, and T. Takeda. 2002. Development of humanized monoclonal antibody TMA-15 which neutralizes Shiga toxin 2. Hybrid. Hybrid. 21:161-168.
13. Levine, M. M. 1998. Immunoprophylaxis of Shiga toxin-producing Escherichia coli infection and disease: strengths and weaknesses of various strategies, p. 405-408. In J. B. Kaper and A. D. O'Brien (ed.), Escherichia coli O157:H7 and other Shiga toxin-producing E. coli strains. ASM Press, Washington, D.C.
14. Ling, H., A. Boodhoo, B. Hazes, M. D. Cummings, G. D. Armstrong, J. L. Brunton, and R. J. Read. 1998. Structure of the Shiga-like toxin I B-pentamer complexed with an analogue of its receptor Gb3. Biochemistry 37:1777-1788.
15. Marques, L. R., M. A. Moore, J. G. Wells, I. K. Wachsmuth, and A. D. O'Brien. 1986. Production of Shiga-like toxin by Escherichia coli. J. Infect. Dis. 154:338-341.
16. Mead, P. S., L. Slutsker, V. Dietz, L. F. McCaig, J. S. Bresee, C. Shapiro, P. M. Griffin, and R. V. Tauxe. 1999. Food-related illness and death in the United States. Emerg. Infect. Dis. 5:607-625.
17. Melton-Celsa, A. R., M. J. Smith, and A. D. O'Brien. March 2005, posting date. Chapter 8.7.8, Shiga toxins: potent poisons, pathogenicity determinants, and pharmacological agents, In R. Curtiss III et al (ed.), EcoSal-Escherichia coli and Salmonella: cellular and molecular biology. ASM Press, Washington, D.C. [Online.] http://www.ecosal.org.
18. Mukherjee, J., K. Chios, D. Fishwild, D. Hudson, S. O'Donnell, S. M. Rich, A. Donohue-Rolfe, and S. Tzipori. 2002. Human Stx2-specific monoclonal antibodies prevent systemic complications of Escherichia coli O157:H7 infection. Infect. Immun. 70:612-619.
19. Mukherjee, J., K. Chios, D. Fishwild, D. Hudson, S. O'Donnell, S. M. Rich, A. Donohue-Rolfe, and S. Tzipori. 2002. Production and characterization of protective human antibodies against Shiga toxin 1. Infect. Immun. 70:5896-5899.
20. Myers, E. W., and W. Miller. 1988. Optimal alignments in linear space. Comput. Appl. Biosci. 4:11-17.
21. Nakao, H., C. Kataoka, N. Kiyokawa, J. Fujimoto, S. Yamasaki, and T. Takeda. 2002. Monoclonal antibody to Shiga toxin 1, which blocks receptor binding and neutralizes cytotoxicity. Microbiol. Immunol. 46:777-780.
22. Nakao, H., N. Kiyokawa, J. Fujimoto, S. Yamasaki, and T. Takeda. 1999. Monoclonal antibody to Shiga toxin 2 which blocks receptor binding and neutralizes cytotoxicity. Infect. Immun. 67:5717-5722.
23. Paton, J. C., and A. W. Paton. 1998. Pathogenesis and diagnosis of Shiga toxin-producing Escherichia coli infections. Clin. Microbiol. Rev. 11:450-479.
24. Shimizu, H., R. A. Field, S. W. Homans, and A. Donohue-Rolfe. 1998. Solution structure of the complex between the B-subunit homopentamer of verotoxin VT-1 from Escherichia coli and the trisaccharide moiety of globotriaosylceramide. Biochemistry 37:11078-11082.
25. Smith, M. J., L. D. Teel, H. M. Carvalho, A. R. Melton-Celsa, and A. D. O'Brien. 2006. Development of a hybrid Shiga holotoxoid vaccine to elicit heterologous protection against Shiga toxins types 1 and 2. Vaccine 24:4122-4129.
26. Strockhine, N. A., L. R. Marques, R. K. Holmes, and A. D. O'Brien. 1985. Characterization of monoclonal antibodies against Shiga-like toxin from Escherichia coli. Infect. Immun. 50:695-700.
27. Strockhine, N. A., L. R. Marques, J. W. Newland, H. W. Smith, R. K. Holmes, and A. D. O'Brien. 1986. Two toxin-converting phages from Escherichia coli O157:H7 strain 933 encode antigenically distinct toxins with similar biologic activities. Infect. Immun. 53:135-140.
28. Tarr, P. I., C. A. Gordon, and W. L. Chandler. 2005. Shiga-toxin- producing Escherichia coli and haemolytic uraemic syndrome. Lancet 365:1073-1086.
29. 3 on verotoxin 1 using NMR residual dipolar coupling measurements. Biochemistry 39:13153-13156.
30. Tzipori, S., H. Karch, K. I. Wachsmuth, R. M. Robins-Browne, A. D. O'Brien, H. Lior, M. L. Cohen, J. Smithers, and M. M. Levine. 1987. Role of a 60-megadalton plasmid and Shiga-like toxins in the pathogenesis of infection caused by enterohemorrhagic Escherichia coli O157:H7 in gnotobiotic piglets. Infect. Immun. 55:3117-3125.
31. Tzipori, S., A. Sheoran, D. Akiyoshi, A. Donohue-Rolfe, and H. Trachtman. 2004. Antibody therapy in the management of Shiga toxin-induced hemolytic uremic syndrome. Clin. Microbiol. Rev. 17:926-941.
32. Tzipori, S., I. K. Wachsmuth, C. Chapman, R. Birden, J. Brittingham, C. Jackson, and J. Hogg. 1986. The pathogenesis of hemorrhagic colitis caused by Escherichia coli O157:H7 in gnotobiotic piglets. J. Infect. Dis. 154:712-716.
33. Wen, S. X., L. D. Teel, N. A. Judge, and A. D. O'Brien. 2006. A plant-based oral vaccine to protect against systemic intoxication by Shiga toxin type 2. Proc. Natl. Acad. Sci. USA 103:7082-7087.
34. Wen, S. X., L. D. Teel, N. A. Judge, and A. D. O'Brien. 2006. Genetic toxoids of Shiga toxin types 1 and 2 protect mice against homologous but not heterologous toxin challenge. Vaccine 24:1142-1148.
35. Yamagami, S., M. Motoki, T. Kimura, H. Izumi, T. Takeda, Y. Katsuura, and Y. Matsumoto. 2001. Efficacy of postinfection treatment with anti-Shiga toxin (Stx) 2 humanized monoclonal antibody TMA-15 in mice lethally challenged with Stx-producing Escherichia coli. J. Infect. Dis. 184:738-742.